AGENUS INC Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High
AGENUS INC (AGEN) had Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High of $19.30 million as of 2021-06-30, per its 10-Q filed 2021-08-09.
Discontinued › Notes
us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh · last filed 2021-08-09
- 2021-06-30: Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High $19.30M.
- 2015-01-31: Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High $6.20M.
| Period end | Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High |
|---|---|
| 2021-06-30 | $19.30M 10-Q · filed 2021-08-09 |
| 2015-01-31 | $6.20M 10-K · filed 2018-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |